参考文献
[1] Ahmed HU, Bosaily ES, Brown LC,et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study [J]. Lancet,2017,389:815-822. DOI:10.1016/S0140-6736(16)32401-1.
[2] 中华医学会泌尿外科学分会,中国前列腺癌联盟.前列腺穿刺中国专家共识[J].中华泌尿外科杂志,2016,37: 241-244. DOI:10.3760/cma.j.issn.1000-6702.2016.04.001.
[3] Eggener SE, Mueller A, Berglund RK,et al. A multi-institutional evaluation of active surveillance for low-risk prostate cancer [J]. J Urol,2013,189:S19-25. DOI:10.1016/j.juro.2012.11.023.
[4] 肖雨,麦智鹏,严维刚,等.根治性前列腺切除术后病理检查对模板引导下经会阴前列腺穿刺活检准确性的再评估 [J].中华泌尿外科杂志,2018,39:14-18. DOI:10.3760/cma.j.issn.1000-6702.2018.01.004.
[5] Woo S, Kim SY, Lee J,et al. PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason score 7 (3+4) prostate cancer [J]. Eur Radiol,2016,26:3580-3587. DOI: 10.1007/s00330-016-4230-9.
[6] Gondo T, Hricak H, Sala E,et al. Multiparametric 3T MRI for the prediction of pathological downgrading after radical prostatectomy in patients with biopsy-proven Gleason score 3+4 prostate cancer [J].Eur Radiol,2014,24:3161-3670. DOI:10.1007/s00330-014-3367-7.
[7] 方志伟,许克新,胡浩,等.第2版前列腺影像报告及数据系统评分在前列腺癌诊断中的价值 [J]. 中华泌尿外科杂志,2018,39,19-23. DOI:10.3760/cma.j.issn.1000-6702.2018.01.005.
[8] Woo S, Suh CH, Kim SY,et al. Diagnostic performance of prostate imaging reporting and data system version 2 for detection of prostate cancer: a systematic review and diagnostic meta-analysis [J]. Eur Urol,2017,72:177-188.DOI:10.1016/j.eururo.2017.01.042.
[9] Epstein JI, Egevad L, Amin MB,et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system [J]. Am J Surg Pathol,2016,40:244-252.DOI:10.1097/PAS.0000000000000530.
[10] Xu N, Wu YP, Chen DN,et al. Can Prostate imaging reporting and data system version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml? [J]. J Cancer Res Clin Oncol,2018,144:987-995.DOI: 10.1007/s00432-018-2616-6.
[11] 赵明,滕晓东,何向蕾,等. 2014年国际泌尿病理协会前列腺癌分级系统新进展和新的预后分组[J].中华病理学杂志,2016,45:673-675. DOI:10.3760/cma.j.issn.0529-5807.2016.10.00.
[12] Bastianjordan M. Magnetic resonance imaging of the prostate and targeted biopsy,comparison of PIRADS and Gleason grading [J]. J Med Imaging Radiat Oncol,2018,62:183-187. DOI:10.1111/1754-9485.12678.
[13] Prasad SM, Sartor AO, Bennett CL,et al. Population-based assessment of determining treatments for prostate Cancer [J]. JAMA Oncol,2015,1:67-68.DOI:10.1001/jamaoncol.2014.183.
[14] Cohen MS, Hanley RS, Kurteva T,et al. Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system:the Lahey Clinic Medical Center experience and an international meta-analysis [J]. Eur Urol,2008,54:371-381.DOI:10.1016/j.eururo.2008.03.049.
[15] Womble PR, Montie JE, Ye Z,et al. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer [J].Eur Urol,2015,67:44-50.DOI:10.1016/j.eururo.2014.08.024.
[16] Cooperberg MR, Cowan JE, Hilton JF,et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer [J]. J Clin Oncol,2011,29:228-234.DOI: 10.1200/JCO.2010.31.4252.
[17] Ross HM, Kryvenko ON, Cowan JE,et al. Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes? [J] Am J Surg Pathol,2012,36:1346-1352.DOI: 10.1097/PAS.0b013e3182556dcd.
[18] Mullins JK, Feng Z, Trock BJ,et al. The impact of anatomical radical retropubic prostatectomy on cancer control:the 30-year anniversary [J]. J Urol, 2012, 188:2219-2224.DOI: 10.1016/j.juro.2012.08.028.
[19] Gondo T, Poon BY, Matsumoto K,et al. Clinical role of pathological downgrading after radical prostatectomy in patients with biopsy confirmed Gleason score 3 + 4 prostate cancer [J]. BJU Int,2015,115: 81-86.DOI:10.1111/bju.12769.
[20] Merrick GS, Delatore A, Butler WM,et al. Transperineal template-guided mapping biopsy identifies pathologic differences between very-low-risk and low-risk prostate cancer: implications for active surveillance [J]. Am J Clin Oncol,2017,40: 53-59.DOI:10.1097/COC.0000000000000105.